Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Signs MOU With Wuhan To Establish First R&D Center In Midwest China; Ranks Number One In China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Pfizer is expanding its presence in central and Western China, having signed a memorandum of understanding with Wuhan National Bioindustry Base Construction and Management Office Nov. 25 to establish a new R&D site in the National Bioindustry Base Biolake in Wuhan, the province capital of Hubei

You may also be interested in...

Pharmaceutical Investment, Expansion Driving Up Real Estate Prices In Asia

One of the largest industrial estates in Southeast Asia is in Cikarang, West Java, Indonesia. It and dozens of clusters are fueling a realignment of the global pharmaceutical industry and pushing up real estate prices across Asia.

Pharma Companies Offering More Perks As Race Heats Up For Top Talent In China

Western-style perks are increasingly being offered to local staff by major pharmaceutical companies seeking to expand quickly in China, according to a recent report.

The Rise Of The Chinese CRO: New Models For An Emerging Player

SHANGHAI - Shrinking margins are adding pressure to contract research organizations in the U.S., and on the other side of the globe, CROs in China are facing the same problem, due to higher labor costs and appreciation of the RMB. Led by WuXi AppTec Inc., the largest Chinese CRO, local CROs are expanding services by entering into new partnering models with multinational clients and preparing for increasing domestic demands

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts